Stoke Therapeutics files $200 million at-the-market stock offeringAug 3FinancingStoke Therapeutics, Inc
Stoke reports full EMPEROR enrollment, sets pre-NDA meeting and Q1 2027 filing startAug 3Quarterly updateStoke Therapeutics, Inc
Biogen posts Q2 2026 results, sets five late-stage readouts over next four quartersJul 29Quarterly updateBiogenfelzartamab
Stoke Therapeutics completes enrollment of 162-patient Phase 3 EMPEROR trial for zorevunersenJun 30Quarterly updateStoke Therapeutics, Inczorevunersen
Sign inSign in